Drug
ANX005
ANX005 is a pharmaceutical drug with 6 clinical trials. Historical success rate of 83.3%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
83.3%
Based on 5 completed trials
Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(17%)
Phase Distribution
Ph phase_3
1
17%
Ph phase_1
2
33%
Ph phase_2
3
50%
Phase Distribution
2
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
83.3%
5 of 6 finished
Non-Completion Rate
16.7%
1 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(5)
Terminated(1)
Detailed Status
Completed5
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (33.3%)
Phase 23 (50.0%)
Phase 31 (16.7%)
Trials by Status
terminated117%
completed583%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_3
Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome
NCT04701164
completedphase_2
Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)
NCT04569435
completedphase_2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
NCT04691570
completedphase_2
An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease
NCT04514367
completedphase_1
A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)
NCT04035135
Clinical Trials (6)
Showing 6 of 6 trials
NCT04701164Phase 3
Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome
NCT04569435Phase 2
Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)
NCT04691570Phase 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
NCT04514367Phase 2
An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease
NCT04035135Phase 1
A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)
NCT03010046Phase 1
Single Dose Study of ANX005 in Healthy Volunteers
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6